Maxigesic(R) IV licensed in eight new European markets

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com





5 March 2021

Maxigesic
®
IV licensed in eight new European markets
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has signed an exclusive
Maxigesic
®
IV licensing agreement for eight new European markets.
The agreement, which due to COVID-19 restrictions was negotiated and sealed
entirely online, is with the Lyon, France-based Aguettant. It means Maxigesic IV will
now be available in 20 of the 27 EU member states, including Germany, France, Italy
and Spain as well as the UK.
Maxigesic IV (Paracetamol 1000mg + Ibuprofen 300mg solution for infusion) is a
patented intravenous formulation developed as a line extension to Maxigesic tablets,
for use post-operatively in hospitals when patients cannot take a medicine orally.
In addition to Spain, Aguettant gains the rights to the medicine in the five Nordic
markets (Finland, Norway, Denmark, Sweden, Iceland), Portugal, and the
Netherlands. AFT expect sales of the medicine in these territories to commence in
early 2022.
AFT Pharmaceuticals Managing Director Dr Hartley Atkinson said: “We are delighted
to have reached this agreement with Aguettant, which specialises in injectable
pharmaceuticals and has a strong sales record in the hospital sector across the EU.
“The agreement extends Maxigesic IV’s footprint across Europe and significantly
expands the market for the medicine. In Spain, for instance, more than 2.5 million
surgeries are performed annually
1
, while a further 1.1 million surgical procedures are
completed in the Nordic countries
2
. Maxigesic IV offers a non-opiate therapeutic
alternative for many of these cases.
“The potential for Maxigesic IV and other dose forms of the medicine is significant. The
market for post-operative pain, which is a subset of Maxigesic’s total addressable
market, is growing rapidly and is forecast by independent market research to reach
US$553 million in 2028 across the 5 major markets of Europe (up from US$178 million in
2019)
3
.
“Particularly, this research has suggested that our Maxigesic IV platform in the same
geographies and market has the potential to grow to generate annual in- market
sales of more than US$88 million
4
. We are looking forward to working with Aguettant
to help us realise its potential,” Dr Atkinson said.
Dr Atkinson also thanked the teams from both companies for their commitment to the
deal in the face of the commercial challenges of the COVID-19 pandemic.

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

“The agreement is a testament to the adaptability and resilience of both Aguettant
and AFT. Despite the difference in time zones and the challenges of the current travel
bans we have put together an agreement that will improve health outcomes in
Europe and drive increases in shareholder value.”
Eric Rougemond, CEO of Aguettant states about the new agreement: “We are
delighted to begin our partnership with AFT. Adding Maxigesic IV formulation to our
portfolio of injectable medicines means we can propose to healthcare professionals
and their patients a brand-new pain management solution for acute moderate pain.
It is fully in line with our objectives to support safer medical practices, make the
everyday work of practitioners easier and improve the quality of life of patients. We
are very much looking forward to starting our commercialization in Spain, Portugal,
The Netherlands and the Nordic countries.”
A major Phase 3 clinical trial conducted in the USA found that Maxigesic IV provided
significantly better pain relief than either paracetamol (acetaminophen) IV or
ibuprofen IV alone in the same doses
5
. Further recently completed exposure trials
have demonstrated the drug’s efficacy and safety in an expanded population group
over a longer treatment period
6
.
Following on from the registration of Maxigesic IV in Australia and New Zealand in mid-
2019, AFT has now licensed the medication in more than 90 countries. Meanwhile, the
tablet form of Maxigesic has been licensed in more than 125 countries.
Released for and on behalf of AFT Pharmaceuticals by Chief Financial Officer
Malcolm Tubby.

For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232


1,3,4
DelveInsight Report (2020). Postoperative Pain Market Insights, Epidemiology and Market
Forecast—2028. DelveInsight.
2.
Calculated using surgery data from Health Statistics for the Nordic Countries. Nordic
Medico-Statistical Committee 100:2013 and World Bank Population Data
5.
Daniels, S.E, Playne, R., Stanescu, I., Zhang, J., Gottlieb, I.J, Atkinson, H.C. (2019). Efficacy
and safety of an intravenous acetaminophen/ibuprofen fixed-dose combination after
bunionectomy: A randomized, double-blind, factorial, placebo- controlled trial. Clinical
Therapeutics 41 (10): 1982-1995. Research sponsored by AFT Pharmaceuticals.
6.
Maxigesic
®
IV Phase 3 Exposure Study. Study ID No. AFT-MXIV-11. NCT04005755. Extending
the safety profile of the post-operative administration of an intravenous acetaminophen/
ibuprofen fixed dose combination: an open-label, multi-center, single arm, multiple dose
study. Submitted for publication

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical business with a broad range of
products, both developed itself and in-licensed from third parties. AFT’s products
cover all major pharmaceutical distribution channels: over the counter, prescription,
and hospital. Historically, AFT’s home markets have been Australia, New Zealand, and
South-East Asia. However, the company is out-licensing its own products to licensees
and distributors to sell in an increasing number of countries around the world. The
company’s intensive Research and Development program forms the basis of its
international sales strategy. For more information about the company, visit our website
www.aftpharm.com

About Aguettant
Aguettant is a family-owned pharmaceutical company dedicated to the
development, industrial production and distribution of innovative injectable
pharmaceutical specialties that meet the demands and the needs of healthcare
professionals and patients. Founded in Lyon, France in 1903, Laboratoire Aguettant’s
growth has been rooted in its engagement with the medical world and its
pharmaceutical expertise in injectable medication. For more information about the
company, visit our website: www.aguettant-corporate.com

About Ferghana Partners (New York, London, Boston) initiated the Aguettant transaction and
provided strategic/financial advisory services to AFT Pharma.